Top-News

Sehen Sie sich dieses Unternehmen an: Rasanter Aufstieg, Branchenrevolution und Jahresumsatz von 50 Mio. $(Anzeige)

Forschungsteam bei der Arbeit im Labor (Symbolbild).

Freitag, 19.05.2017 09:05 von PR Newswire | Aufrufe: 56

PharmaMar Announces New Data with its Compounds Yondelis® and Lurbinectedin During ASCO 2017

Forschungsteam bei der Arbeit im Labor (Symbolbild). © gorodenkoff / iStock / Getty Images Plus / Getty Images http://www.gettyimages.de

PR Newswire

MADRID, May 19, 2017

MADRID, May 19, 2017 /PRNewswire/ --

PharmaMar (MCE: PHM) will present data obtained from various clinical studies for its activated transcription inhibitors, Yondelis^® and lurbinectedin, during the 53^rd Congress of the American Society of Clinical Oncology (ASCO) that will be held from the 2^nd to the 6^th of June in Chicago (USA).

(Logo: http://photos.prnewswire.com/prnh/20150203/727958-b )

During this congress, PharmaMar will participate with various presentations for Yondelis® in malignant pleural mesothelioma, along with the data of a prospective study of the combination with radiotherapy in soft tissue sarcoma.

The Company will also present data for lurbinectedin (PM1183) for the treatment of endometrial cancer and BRCA 2-associated metastatic breast cancer. The results will also be presented on a Phase I study that evaluated the combination of lurbinectedin with olaparib in patients with advanced solid tumors.

"After the positive results obtained in endometrial cancer with lurbinectedin, as a single agent and in combination with doxorubicin (abstract 6658), we plan to initiate a pivotal Phase III study. We have reached an agreement with the US FDA on the design of the study", explains Dr Arturo Soto, Head of Clinical Development at the Oncology Business Unit at PharmaMar. "We will continue with our commitment to finding innovative solutions for cancer patients from compounds of a marine origin that have the characteristic for combating cancer with a novel mechanism of action", states.

The studies presented during this congress are available on http://abstracts.asco.org

ARIVA.DE Börsen-Geflüster

Kurse

Pharma Mar

28,74 €

-0,62%

PREMIER ROYALTY

0,00%

Principle studies to be presented at ASCO 2017

Lurbinectedin

Activity of lurbinectedin (PM01183) as single agent and in combination in patients with endometrial cancer. (Abstract 5586)

Poster Board: #408. Saturday 3 of June from 13:15 to 16:45. Hall A

Lead author: Martin David Forster, MBBS, MRCP, FRCP, PhD, University College London Hospitals

Antitumor activity of trabectedin and lurbinectedin in germline BRCA2 carriers with metastatic breast cancer (MBC) as compared to BRCA1 carriers: Analysis of two phase II trials. (Abstract 574)

Poster Board: #174. Sunday, 4 of June from 8:30 to 11:30. Hall A

Lead author: Judith Balmana Gelpi, MD PhD, Hospital Vall d'Hebron

Phase I study to evaluate the tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) of PM01183 (Lurbinectedin) in combination with olaparib in patients with advanced solid tumors. (Abstract 5573)

Poster Board: #395. Saturday, 3 of June from 13:15 to 16:45. Hall A

Lead autjor: Andres Poveda, MD, Clinical Area of Gynecologic Oncology, Instituto Valenciano de Oncología (IVO)

Yondelis^® (trabectedin)

Trabectedin (T) as second line treatment option for patients with epithelioid malignant pleural mesothelioma (MPM) in progression following pemetrexed/platin-derivates chemotherapy: ATREUS trial. (Abstract 8513)

Poster Board: #249. Saturday, 3 of June from 13:15 to 14:30. Hall D2

Laed author: Diego Luigi Cortinovis, MD, Azienda Ospedaliera San Gerardo

Trabectedin for advanced soft tissue sarcoma: Ten-year real-life perspective. (Abstract 11060)

Poster Board: #383. Sunday, 4 of June from 8:00 to 11:30. Hall A

Lead author: Sivan Shamai, MD, Tel Aviv Medical Center and Sackler School of Medicine

Trabectedin and radiotherapy in soft-tissue sarcoma (TRASTS) study: An international, prospective, phase I/II trial-A collaborative Spanish (GEIS), Italian (ISG), and French (FSG) groups study. (Abstract 11061)

Poster Board: #384. Sunday, 4 of June from 8:00 to 11:30. Hall A

Laed author: Alessandro Gronchi, MD, Fondazione IRCCS Istituto Nazionale dei Tumori

Correlation between a new growth modulation index (GMI)-based Geistra score and efficacy outcomes in patients (PTS) with advanced soft tissue sarcomas (ASTS) treated with trabectedin (T): A Spanish group for research on sarcomas (GEIS-38 study). (Abstract 11070)

Poster Board: #393. Sunday, 4 of June from 8:00 to 11:30. Hall A

Laed author: Javier Martinez-Trufero, PhD, Hospital Miguel Servet

Predictive role of FAS for trabectedin in second lines of advanced soft tissue sarcoma (ASTS): A Spanish group for research on sarcoma (GEIS) study. (Abstract 11071)

Poster Board: #394. Sunday, 4 of June from 8:00 to 11:30. Hall A

Laed author: Javier Martin Broto, MD, PhD, Virgen del Rocio University Hospital, Institute of Biomedicine Research (IBIS)

Media Relations (+34-638-79-62-15) and Investor Relations (+34-914444500)

Mehr Nachrichten zur PREMIER ROYALTY Aktie kostenlos abonnieren

E-Mail-Adresse

Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.